Literature DB >> 28390776

Calciphylaxis: Beyond CKD-MBD.

María Fernández1, Enrique Morales2, Eduardo Gutierrez1, Natalia Polanco1, Eduardo Hernández1, Eva Mérida1, Manuel Praga1.   

Abstract

INTRODUCTION: Calcific uraemic arteriolopathy (CUA), also called calciphylaxis, is a rare but potentially fatal vascular disorder that almost exclusively affects patients with chronic renal failure. The objective of this study was to analyse various risk factors for developing CUA and its subsequent clinical course according to the treatment received.
MATERIALS AND METHODS: A retrospective study that included patients diagnosed with CUA from December 1999 to December 2015. Various risk factors, clinical course and treatment options were analysed.
RESULTS: A total of 28 patients (53.6% females) with a mean age of 67.2±11.8 (38-88) years were included. At the time of diagnosis, 53.6% were on haemodialysis, 25% were kidney transplant patients and 21.4% had normal renal function. The use of steroids (100%, P=.001) was the main risk factor in renal transplant patients. Skin lesions resolved in 60.7% (especially in those receiving multitargeted therapy). Patient survival at 12 months was 29% in transplant patients, 57% in haemodialysis patients and 100% in normal renal function patients (log-rank 6.88, P=.032). Chronic renal failure (P=.03) and hypoalbuminaemia (P=.02) were the main risk factor for CUA mortality.
CONCLUSIONS: Although the incidence of CUA remains low, CUA mortality is very high, Special attention to its occurrence in kidney transplant patients and «non-renal» CUA forms is required. Oral anticoagulants and steroids appear to be the main risk factors, CUA is a challenge; a registry of patients and determining standard therapy are required.
Copyright © 2017 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Anticoagulantes orales; Calcifilaxis; Calciphylaxis; Chronic renal failure; Formas no renales; Insuficiencia renal crónica; Mortalidad; Mortality; Non-renal forms; Oral anticoagulants

Mesh:

Substances:

Year:  2017        PMID: 28390776     DOI: 10.1016/j.nefro.2017.02.006

Source DB:  PubMed          Journal:  Nefrologia        ISSN: 0211-6995            Impact factor:   2.033


  3 in total

Review 1.  Calciphylaxis and its diagnosis: A review.

Authors:  Deepak Baby; Meenakshi Upadhyay; M Derick Joseph; Swati Joshi Asopa; Basanta Kumar Choudhury; Jagadish Prasad Rajguru; Shivangi Gupta
Journal:  J Family Med Prim Care       Date:  2019-09-30

2.  Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study.

Authors:  Tadao Akizawa; Ryutaro Shimazaki; Masanari Shiramoto; Masafumi Fukagawa
Journal:  Clin Drug Investig       Date:  2018-10       Impact factor: 2.859

3.  First-in-Human Phase I Study of the Novel Injectable Calcimimetic Agent Upacicalcet in Healthy Adult Japanese Participants.

Authors:  Fumihiko Koiwa; Rie Yazawa; Masafumi Fukagawa; Daisuke Honda; Tadao Akizawa
Journal:  Drugs R D       Date:  2022-03-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.